Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...
The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...
Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
The trio all have late-stage therapies with blockbuster potential.
Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.
The company released positive results for its lead therapy.